A Dipped TSX Index Stock to Hold in Your TFSA Forever

Why TFSA investors should pop Jamieson Wellness Inc. (TSX:JWEL) in their TFSAs after the recent overblown dip.

| More on:

Jamieson Wellness (TSX:JWEL) fell off a cliff following the release of its third-quarter earnings, which missed on both the top and bottom line thanks in big part to timing issues in the company’s strategic partners business.

Third-quarter numbers looked “malnourished”

The company clocked in $90 million in revenue, up 3.7% year over year, but falling short of analyst expectations of $90.7 million. Adjusted EBITDA came in at $17.9 million, again missing the analyst consensus of $19.1 million. The muted top- and bottom-line performance turned out to be a one-two punch to the gut of investors who’d ditched their shares to the curb following the double miss that I believe was more benign than what the public may think.

The vitamins, minerals, and supplements (VMS) scene is very competitive, and although it may appear Jamieson is turning out to be a dud, I’d say the recent weakness isn’t at all indicative of weakness in the brand. Rather, the strategic partners segment had some major wrinkles that can and will be ironed out in due time. The strategic partners business fell 2.3% year over year due to raw material delays that’s a one-off issue that long-term thinkers should be shrugging off.

At the time of writing, Jamieson is down over 31% from peak levels reached in September and looks to be a compelling long-term buying opportunity for contrarian growth investors seeking to profit from unique generational tailwinds.

Moreover, Jamieson is on the cusp of a very ambitious global expansion that could bring forth double-digit EPS growth numbers. With Jamieson’s Chinese expedition underway, we could be in for the first chapter of an incredible growth story.

Forward-looking growth is all about the red-hot Chinese market

China is no stranger to the green-capped Canadian vitamin kingpin.

Jamieson is already a top five foreign brand within the Chinese market according to Jamieson CEO Mark Hornick, and that’s before the company has been granted the opportunity to make its big splash! As we head into 2019, Jamieson is getting ready to jump off its diving board, and all that’s holding the company back from tremendous success in the Chinese market is the pending approval of various filings that must be in full compliance to a rather lengthy list of stringent Chinese regulations.

Who said vitamins were simple?

As we head into 2019, we could see Jamieson products hit Chinese shelves, potentially fueling a new source of explosive growth that could rocket Jamieson shares out of the gutter. For Q3, Jamieson filed two products that should be approved for launch at some point over the next year or so.

Foolish takeaway

Jamieson’s latest quarterly results stunk. There’s no sugar-coating that. I believe the results weren’t as bad as the public was led to believe, however, especially given the fact that Jamieson is about to break into a hot Chinese market, where its product lineup could put up a good fight with the incumbent players.

I think Jamieson’s a strong buy after falling back into the $18 levels. The 2% dividend is just a bonus for investors who dare to jump in after the sharp decline. If you’re a young investor who’s hungry for growth at a value price, pop Jamieson in your TFSA, and your returns will probably be healthy in a year from now.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned.

More on Investing

Train cars pass over trestle bridge in the mountains
Dividend Stocks

Is CNR Stock a Buy, Sell, or Hold for 2025?

Can CNR stock continue its long-term outperformance into 2025 and beyond? Let's explore whether now is a good time to…

Read more »

engineer at wind farm
Energy Stocks

Invest $20,000 in This Dividend Stock for $100 in Monthly Passive Income

This dividend stock has it all – a strong outlook, monthly income, and even more to consider buying today.

Read more »

Hourglass and stock price chart
Stock Market

It’s Not Too Late: Invest in These TSX Growth Stocks Now

Solid fundamentals of these top TSX growth stocks could help them maintain strong upward momentum in the years to come.

Read more »

coins jump into piggy bank
Dividend Stocks

The Smartest Dividend Stocks to Buy With $500 Right Now

These top dividend stocks both offer attractive yields and trade off their highs, making them two of the best to…

Read more »

stocks climbing green bull market
Stocks for Beginners

3 TSX Stocks Soaring Higher With No Signs of Slowing

Don't ignore stocks just because they look like they're at a high price. Instead, see exactly why they've driven so…

Read more »

dividends can compound over time
Bank Stocks

Is TD Bank Stock a Buy for Its 5.2% Dividend Yield?

TD Bank stock offers a rare 5.2% dividend yield—can it rebound from challenges and reward contrarian investors? Here's what to…

Read more »

chart reflected in eyeglass lenses
Investing

How Should a Beginner Invest in Stocks? Start With This Index Fund

This Vanguard index fund is the perfect way to start a Canadian investment portfolio.

Read more »

analyze data
Bank Stocks

Is BMO Stock a Buy for its 4.7% Dividend Yield?

Bank of Montreal is up 20% since late August. Are more gains on the way?

Read more »